PDA-001 + PDA-002

PDA-001 and PDA-002 are allogeneic, unmodified mesenchymal-like adherent stromal cell (MLASC) therapies derived from healthy, full-term human placental tissue, developed by Celularity. PDA-001 is formulated for intravenous infusion, while PDA-002 is designed for local injection. These therapies exert their therapeutic effects through immunomodulation, reduction of inflammation, and promotion of angiogenesis and tissue regeneration. PDA-002 has completed Phase 2 clinical trials for diabetic foot ulcers (DFU), particularly in patients with peripheral artery disease, demonstrating safety and efficacy in promoting wound healing. PDA-001 has been investigated for immune-mediated conditions such as Crohn's disease and multiple sclerosis. These products are often grouped together in Celularity's pipeline for the treatment of Crohn's disease and diabetic foot ulcers.

Other names

MLASCmesenchymal-like adherent stromal cells